Volume 49, Issue 4, Pages 666-674 (April 2006) Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy- Naive Androgen Independent Prostate Cancer  Robert Svatek, Pierre I. Karakiewicz, Michael Shulman, Jose Karam, Paul Perrotte, Elie Benaim  European Urology  Volume 49, Issue 4, Pages 666-674 (April 2006) DOI: 10.1016/j.eururo.2005.11.032 Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 1 Kaplan-Meier estimates of AIPC-specific survival, overall and other-cause survival with 95% confidence intervals. European Urology 2006 49, 666-674DOI: (10.1016/j.eururo.2005.11.032) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 2 The effect (and its 95% confidence interval) of each predictor on log relative hazard of androgen insensitive prostate cancer-specific survival. All other remaining predictors are held constant. European Urology 2006 49, 666-674DOI: (10.1016/j.eururo.2005.11.032) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 3 Calibration plots for prediction of AIPC-specific survival at 12–60 months. Nomogram data are shown in the left hand column and recursive partitioning data are shown in the right hand column. European Urology 2006 49, 666-674DOI: (10.1016/j.eururo.2005.11.032) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 4 Nomogram predicting AIPC-specific survival. PSA ADT init.: PSA at start of androgen deprivation therapy ADT: androgen deprivation therapy AIPC: androgen insensitive prostate cancer Time ADT≥AIPC(M): Time from ADT to AIPC diagnosis. 12(M)AIPC-Spec.Surv. – probability of AIPC-specific survival at 12 months after AIPC diagnosis 24(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 24 months after AIPC diagnosis 36(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 36 months after AIPC diagnosis 48(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 48 months after AIPC diagnosis 60(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 60 months after AIPC diagnosis Instruction for physician: Locate the patient’s PSA at the time of androgen-deprivation therapy initiation (PSA at ADT init.) on the PSA at ADT init. axis. Draw a line straight upwards to the Points axis to determine how many points towards AIPC-specific survival the patient receives. Repeat this process for the other predictors, each time drawing a straight upward line to the Points axis. Sum the points for each predictor and locate this sum on the Total Points axis. Draw a line straight down to find the patient’s probability of AIPC-specific survival at 12, 24, 36, 48 and 60 months after androgen insensitive prostate cancer (AIPC) diagnosis, assuming he does not die of another cause first. European Urology 2006 49, 666-674DOI: (10.1016/j.eururo.2005.11.032) Copyright © 2005 Elsevier B.V. Terms and Conditions